Teacher
Sandra Lourenço Ferreira

Resume

Sandra Lourenço Ferreira. Completed the Mestrado in Ciências Farmacêuticas in 2017 by Instituto Superior de Ciências da Saúde Egas Moniz and Mestrado in Mestrado Integrado em Ciências Farmacêuticas in 2017/11 by Instituto Superior de Ciências da Saúde Egas Moniz. Attends the Doktor (PhD) in Ciências da Saúde (D) (parceria U. Alcalá) by Universidade Lusófona de Humanidades e Tecnologias Centro de Investigação em Biociências e Tecnologias da Saúde since 2020/09. Is Assistant Professor in Universidade Lusófona de Humanidades e Tecnologias Escola de Ciências e Tecnologias da Saúde and Researcher in Universidade Lusófona de Humanidades e Tecnologias Centro de Investigação em Biociências e Tecnologias da Saúde. Published 3 articles in journals. Organized 6 event(s). Participated in 20 event(s). Participates and/or participated as Master Student Fellow in 1 project(s) and Other in 1 project(s). Works in the area(s) of Medical and Health Sciences with emphasis on Basic Medicine with emphasis on Pharmacology and pharmacy, Exact Sciences with emphasis on Computer and Information Sciences with emphasis on Bioinformatics, Exact Sciences with emphasis on Chemical Sciences and Natural sciences with emphasis on Biological Sciences with emphasis on Biology. In his curriculum Ciência Vitae the most frequent terms in the context of scientific, technological and artistic-cultural output are: LOXL2; breast cancer; Cancer research; .

Graus

• Mestrado
  Mestrado Integrado em Ciências Farmacêuticas
• Doktor (PhD)
  Ciências da Saúde (D) (parceria U. Alcalá)
• Outros
  Formação Avançada em Monitorização de Ensaios Clínicos
• Pós-Graduação
  YOUNG PHARMACISTS MANAGEMENT
• Outros
  Curso de formação Avançada, Fundamentos em cultura celular
• Outros
  Curso de formação Avançada, Manipulação e análise da expressão genética
• Pós-Graduação
  Data Science com Python
• Outros
  Bioinformática Molecular Curso Prático Online
• Outros
  Novel Challenges in Toxicology
• Outros
  Full Spectrum Flow Cytometry Course
• Outros
  “QuantStudio Real Time PCR SmartStart Orientation – Gene Expression (Relative Quantification) - Overview
• Mestrado
  Ciências Farmacêuticas

Publicações

Artigo em revista

• 2023-09-05, P03-18: Lysyl oxidase like 2: an enzyme at the crossroad of Toxicology and Pharmacology, Toxicology Letters
• 2023, Evaluation of the Lysyl Oxidase-Like 2 (LOXL2) inhibitory activity of pimaranes and their glycosyl derivatives, Journal Biomedical and Biopharmaceutical Research
• 2022-04-06, Polyphenols and Their Metabolites in Renal Diseases: An Overview, Foods
• 2021-02-19, LOXL2 Inhibitors and Breast Cancer Progression, Antioxidants

Artigo em jornal

• 2022-06-21, Lysyl Oxidases Expression and Breast Cancer Progression: A Bioinformatic Analysis, Front. Pharmacol

Entrada de enciclopédia

• LOXL2 Inhibitors and Breast Cancer Progression, Scholarly Community Encycolpedia

Resumo em conferência

• 2023-09-06, Lysyl Oxidase Like 2: an enzyme at the crossroad of Toxicology and Pharmacology, 57th Congress of the European Societies of Toxicology (EUROTOX)
• 2023-02, A NOVEL LYSYL OXIDASE LIKE 2 INHIBITOR DECREASES BREAST CANCER CELLS MIGRATION, 53rd Meeting of the Portuguese Society of Pharmacology, 41st Meeting of Clinical Pharmacology and 22nd Meeting of Toxicology
• 2022-07-14, Lysyl oxidase like 2 as a therapeutic target for breast cancer: bioinformatics analysis and biochemical evaluation of 4-thiazolidinone derivatives, FEBS
• 2021-10-06, Bioinformatics analysis for Lysyl Oxidases as therapeutic targets for breast cancer, Molecular Analysis for Precision Oncology Congress 2021

Poster em conferência

• 2023-11-25, Exploring the Multifaceted Potential of EPCU in Targeting Tumorigenesis and Hormone Regulation, 2nd Asian Council Symposium
• 2022-07, Targeting lysyl oxidases for breast cancertherapy: bioinformatic analysis and evaluationof 4-thiazolidinone derivatives as LOXL2inhibitors, The Biochemistry Global Summit, 25th IUBMB Congress, 46th FEBS Congress, 15th PABMB Congress
• 2021-11, Evaluation of the Lysyl Oxidase Like 2 (LOXL2) inhibitory activity of a natural pimarane and its sugar derivatives, II Bio.Natural-Bioactive Natural Products Research Meeting
• 2021-10, Lysyl Oxidases in the pathophysiology of breast cancer: a bioinformatics approach, 56º Congresso Anual da SBFIS Online
• 2021-10, Bioinformatics analysis for Lysyl Oxidases as therapeutic targets for breast cancer. Molecular, Analysis for Precision Oncology Virtual Congress 2021
• 2021-09-24, Lisil Oxidases como possíveis alvos terapêuticos para o cancro da mama: análise baseada na bioinformática
• 2021-05-18, LOXL2 inhibitory activity of pimaranes from medicinal plants, conferência do Dia Internacional do Fascínio das Plantas
• 2020-11-23, LOXL2 inhibitory activity of ultrasound aqueous extracts from medicinal plants, IV jornadas CBIOS